Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA

被引：0
|
作者：
D Călugăru
M Călugăru
机构：
[1] University of Medicine,Department of Ophthalmology
来源：
Eye | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1113 / 1113
相关论文
共 50 条
  • [31] Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
    S Nghiem-Buffet
    S Baillif
    S Regnier
    A Skelly
    N Yu
    A Sodi
    Eye, 2017, 31 : 1113 - 1114
  • [32] INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION A Randomized Clinical Trial
    de Salles, Manuel Casselholm
    Amren, Urban
    Kvanta, Anders
    Epstein, David L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (07): : 1370 - 1376
  • [33] Ranibizumab for Central Retinal Vein Occlusion in Paediatrics Patients
    Castro, Veronica
    Navarro, Catalina
    Montero, Javier
    OPHTHALMOLOGICA, 2014, 232 : 45 - 45
  • [34] Branch and central retinal vein occlusion: clinical pearls from trials of ranibizumab
    Liu, Mimi
    Eichenbaum, David
    Taylor, Sarah
    Wang, Pin-wen
    Quezada-Ruiz, Carlos
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [35] INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE
    Brynskov, Troels
    Kemp, Henrik
    Sorensen, Torben L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (08): : 1637 - 1643
  • [36] COST-EFFECTIVENESS OF AFLIBERCEPT IN THE TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION IN TURKEY
    Tunalioglu, A.
    Ozdemir, O.
    Eldem, B.
    Unlu, N.
    Alp, M. N.
    Saatci, A. O.
    Ozmert, E.
    Deger, C.
    Asan, S.
    Sumer, F.
    Parali, E.
    Ozel, M. O.
    Erdal, E.
    Sar, C.
    VALUE IN HEALTH, 2015, 18 (03) : A181 - A182
  • [37] Efficacy-Based Aflibercept Treatment Regimen for Central Retinal Vein Occlusion
    Shimura, Masahiko
    Utsumi, Takuya
    Imazeki, Makoto
    Yasuda, Kanako
    Noma, Hidetaka
    OPHTHALMOLOGY RETINA, 2021, 5 (11): : 1177 - 1179
  • [38] Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study
    Rouvas, Alexander
    Petrou, Petros
    Vergados, Ioannis
    Pechtasides, Dimitrios
    Liarakos, Vasilios
    Mitsopoulou, Maria
    Ladas, Ioannis
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (12) : 1609 - 1616
  • [39] Clinical outcomes after switch from aflibercept to ranibizumab for macular edema secondary to retinal vein occlusion
    Wibbelsman, Turner D.
    Calem, Daniel B.
    Obeid, Anthony
    Mellen, Phoebe L.
    Konkoly, Michelle A.
    Velez, Michael R.
    Sioufi, Kareem
    Borkar, Durga S.
    Pandit, Ravi
    Klufas, Michael A.
    Hsu, Jason
    Regillo, Carl
    Ho, Allen C.
    Gupta, Omesh P.
    Spirn, Marc J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [40] Anti-Vascular Endothelial Growth Factor Treatment Patterns and Outcomes in Retinal Vein Occlusion in Routine Clinical Practice
    Xu, Colin
    Kim, Erin
    Valentim, Carolina Carvalho Soares
    Seth, Kanika
    Muste, Justin
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
12345